Evommune, Inc. cash flow to debt ratio of -3.71K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Evommune, Inc.'s free cash flow has decreased 31.56% from $-58.28M last year to $-76.68M, signaling decreasing performance

Evommune, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Evommune, Inc.'s debt has increased relative to shareholder equity from -1.34 last year to 0.03 today, signaling weakened financials

Evommune, Inc. has a net cash position, so leverage is healthy.

Evommune, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Evommune, Inc.'s profit margin has increased (-0.81%) in the last year from -954.40% to -946.68%, signaling increasing performance

Evommune, Inc.'s short-term assets of $153.48M exceed its short-term liabilities of $17.91M

Evommune, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Evommune, Inc.'s return on equity of -62.63%, is lower than 15.00%, indicating bad performance

Evommune, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Evommune, Inc. has insufficient public price history to evaluate earnings stability.

Evommune, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Evommune, Inc. has negative free cash flow, indicating cash burn

Evommune, Inc.'s yearly earnings has decreased 3.09% since last year from $-66.81M to $-68.87M, signaling decreasing performance

Evommune, Inc.'s yearly revenue has increased 85.71% since last year from $7.00M to $13.00M, signaling increasing performance

ROIC -35.66% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Evommune, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Evommune, Inc. has insufficient public price history to evaluate revenue consistency.

Evommune, Inc. has insufficient public price history to evaluate ROE consistency.

Evommune, Inc. has insufficient data to evaluate this check.

Evommune, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Evommune, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Evommune, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Evommune, Inc. has insufficient data to evaluate this check.

Evommune, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Evommune, Inc. has a price-to-book ratio of 1.83x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Evommune, Inc. has a price-to-sales ratio of 50.85x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue